April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
Project PrIDE demonstration studies in New York and Houston show that properly funded and well-designed outreach programs can impact a city's ability to provide better HIV services for underserved populations.
Black transgender women and the HIV care continuum; PrEP uptake potential among trans women; an update on U.S. mother-to-child HIV transmission; is extra measles vaccination necessary?
The findings mark a crucial point in the history of PrEP delivery among trans women, as they offer clarity for health care providers, PrEP outreach campaigns, and trans women using estradiol as feminizing hormone therapy.
PrEP's success should not be measured by quantity but by quality. The basic level of health care accessibility should allow people high-quality health care provided by premiere providers and frontline staff.
The more than 300 transgender women in the pivotal iPrEx pre-exposure prophylaxis (PrEP) trial had similar overall HIV infection rates whether they were randomized to take tenofovir/emtricitabine (Truvada) or placebo, but those with drug levels indic...
In response to mounting evidence of the prevention benefits of pre-exposure prophylaxis (PrEP) use by HIV-negative gay and bisexual men, a discussion recently emerged about the perceived exclusion of transgender men from PrEP research studies.
The conference, which opened with loss and determination to persevere -- begins to close, as delegates share the last round of studies, strategies and stories of struggle before returning to the comfort or challenges of home.